CLTX has demonstrated specific and selective binding to membrane-bound MMP-2 and minimal binding to normal brain tissue, therefore CAR-T cells engineered to incorporate CTLX as an antigen recognition domain are considered a promising approach for MMP-2 positive glioblastoma treatment, redirecting cytotoxic T cells towards glioblastoma cells (171). This evidence concerns the gene MMP2 and glioblastoma.